Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

W. Mahaffey, Kenneth; Jardine, Meg; Bompoint, Séverine; P. Cannon, Christopher; Neal, Bruce; J.L. Heerspink, Hiddo; M. Charytan, David; Edwards, Robert; Agarwal, Rajiv; L. Bakris, George; Bull, Scott; Capuano, George; de Zeeuw, Dick; Greene, Tom; Levin, Adeera; A. Pollock, Carol; Sun, Tao; C. Wheeler, David; Yavin, Yshai; Zhang, Hong; Zinman, Bernard; Rosenthal, Norman; M. Brenner, Barry; Perkovic, Vlado; behalf of the CREDENCE Study Investigators, On

doi:10.1161/circulationaha.119.042007

Public

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Published in Circulation • Jul 11, 2019

Authors:

Kenneth W. Mahaffey

Meg Jardine

Séverine Bompoint

Abstract

BACKGROUND: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). METHODS: In CREDENC...

Subject

Medicine

Canagliflozin

Diabetes mellitus

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!